BioMarin Enrolls First Patient in Phase 1/2 Trial of NAGLU Fusion Protein BMN 250 for Treatment of MPS IIIB (Sanfilippo B Syndrome)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) | Delayed: 55.95 -0.68 (1.2%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $56.63 | 52 Week High | $108.96 | |||
| Open | $56.68 | 52 Week Low | $62.12 | |||
| Day High | $56.81 | P/E | N/A | |||
| Day Low | $55.24 | EPS | $-1.27 | |||
| Volume | 1,682,821 | |||||
